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Background
The plant alkaloid ibogaine has shown promising anti-
addictive properties in animals and humans. Although not
licensed as a therapeutic drug, and despite evidence that
ibogaine may disturb the rhythm of the heart, this alkaloid
is used as an anti-addiction drug in alternative medicine.
We have recently reported that therapeutic concentrations
of ibogaine inhibit human ERG (hERG) potassium chan-
nels, and thereby uncovered a mechanism by which the
drug may induce life-threatening cardiac arrhythmias.
Methods
Here, to assess the drug’s proarrhythmic potential in more
detail, we studied the effects of ibogaine and its congener
18-methoxycoronaridine (18-MC) on various cardiac vol-
tage-gated ion channels by using the whole cell patch
clamp technique. Besides heterologously expressed ion
channels in TSA-201 cells, native channels in isolated
mouse and guinea pig ventricular cardiomyocytes were
also studied. Finally, we performed computer simulations
to estimate drug effects on the human cardiac action
potential (AP).
Results
We confirmed that heterologously expressed hERG cur-
rents are reduced by ibogaine in low micromolar concen-
trations (IC50, 4 µM). Moreover, at higher concentration,
the drug also reduced human NaV1.5 sodium currents.
Experiments on mouse cardiomyocytes confirmed that
ibogaine also inhibits voltage-gated ion channels in their
native environment. 18-MC also reduced cardiac ion cur-
rents, but less potently than ibogaine. Although blocking
hERG channels, ibogaine did not prolong the AP in gui-
nea-pig cardiomyocytes at low micromolar concentrations.
Higher concentrations (>10 µM) even shortened the AP.
Finally, implementation of ibogaine’s inhibitory effects on
ion channels in a computer model of a human ventricular
cardiomyocyte suggested that calcium channel blockade
by the drug counteracts the AP-prolonging effect gener-
ated by hERG inhibition.
Conclusions
Because ibogaine inhibits cardiac ion channels in thera-
peutic concentrations, the drug is potentially proarrhyth-
mic. The risk of its administration, however, is possibly
reduced by the fact that the drug also shows antiarrhyth-
mic properties.
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